Apeiron signs £207m deal with Glaxo
19. March 2010 Apeiron Biologics AG has granted GlaxoSmithKline plc (GSK) exclusive rights to APN01, a recombinant form of human Angiotensin Converting Enzyme 2, (rhACE2) for treating Acute Respiratory Distress Syndrome (ARDS).
